| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
506128 Stock Overview
Parnax Lab Limited manufactures and sells pharmaceutical formulations in India.
Parnax Lab Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹99.20 |
| 52 Week High | ₹169.90 |
| 52 Week Low | ₹22.00 |
| Beta | 1.14 |
| 1 Month Change | 11.09% |
| 3 Month Change | -22.04% |
| 1 Year Change | 284.50% |
| 3 Year Change | 312.47% |
| 5 Year Change | 77.30% |
| Change since IPO | 1,080.95% |
Recent News & Updates
Shareholder Returns
| 506128 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 5.5% | 0.2% | 1.9% |
| 1Y | 284.5% | -11.7% | 9.1% |
Return vs Industry: 506128 exceeded the Indian Pharmaceuticals industry which returned -11.7% over the past year.
Return vs Market: 506128 exceeded the Indian Market which returned 9.1% over the past year.
Price Volatility
| 506128 volatility | |
|---|---|
| 506128 Average Weekly Movement | 9.0% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: 506128 is more volatile than 90% of Indian stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: 506128's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1982 | 10 | Prakash Shah | https://www.naxparlab.com |
Parnax Lab Limited manufactures and sells pharmaceutical formulations in India. It offers pharmaceutical products in the form of liquids, ointments, gels, creams, tablets, and capsules; and medicinal products. The company also provides cosmetic products; herbal/ayurvedic products; and nutraceutical products.
Parnax Lab Limited Fundamentals Summary
| 506128 fundamental statistics | |
|---|---|
| Market Cap | ₹1.14b |
| Earnings (TTM) | ₹91.98m |
| Revenue (TTM) | ₹1.71b |
12.4x
P/E Ratio0.7x
P/S RatioIs 506128 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 506128 income statement (TTM) | |
|---|---|
| Revenue | ₹1.71b |
| Cost of Revenue | ₹929.90m |
| Gross Profit | ₹780.87m |
| Other Expenses | ₹688.89m |
| Earnings | ₹91.98m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 8.01 |
| Gross Margin | 45.64% |
| Net Profit Margin | 5.38% |
| Debt/Equity Ratio | 143.1% |
How did 506128 perform over the long term?
See historical performance and comparison